Evidence map›Paper›PMID 41554753›Full record

ArticleNature communications2026

Palmitic acid-triggered B7H3 palmitoylation promotes immune escape.

Zejun Rao, Changsheng Huang, Qi Wu, Mao Li, Anyi Liu, Tong Zhu, Wangshuo Yang, Lanlan Yin, Shengyu Zhu, Xiaowei She and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Zejun RaoGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Changsheng HuangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0000-0002-9301-1635
Qi WuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Mao LiGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0009-0003-9502-8515
Anyi LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Tong ZhuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Wangshuo YangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Lanlan YinGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Shengyu ZhuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0000-0002-2371-1476
Xiaowei SheGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Chengxin YuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Lang LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Pengcheng LiGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yucong BaiGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Dongjing ZhangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Tianci XieGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Xiang LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Lu LiuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Feng XuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Guihua WangGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0000-0001-5423-9357
Junbo HuGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. jbhu@tjh.tjmu.edu.cn.ORCID http://orcid.org/0000-0002-3582-999X
Xuelai LuoGI Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. luoxl@tjh.tjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer responds poorly to immune checkpoint blockade in most patients with microsatellite-stable (MSS) tumors, highlighting the need for alternative targets. B7H3 (CD276) is an immune checkpoint protein that is frequently overexpressed in tumors, but how it is maintained at high protein levels is unclear. Here we show that palmitic acid (PA) promotes B7H3 palmitoylation by the palmitoyltransferase ZDHHC24 at cysteine 496. This modification prevents B7H3 from binding to sequestosome 1 (SQSTM1, also called p62), limiting autophagic degradation and stabilizing B7H3, which suppresses CD8

Indexed as

B7 AntigensColorectal NeoplasmsLipoylationPalmitic AcidTumor EscapeAcyltransferasesAnimalsCD8-Positive T-LymphocytesCell Line, TumorColitisHumansMiceMice, Inbred C57BLAcyltransferasesB7 AntigensCD276 protein, humanPalmitic Acid

Identifiers

PMID41554753
PMCPMC12917163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.